ImmuONE announces launch of first product ImmuPHAGE to understand the safety of inhaled substances in vitro 

Hertfordshire, UK / July 2023 – ImmuONE today announced the launch of  ImmuPHAGE TM an in vitro assay that can evaluate how substances interact with the macrophage white blood cells found in the deep lung’s alveoli. 

“Laboratories across the world are recognising the need for more accurate and sustainable ways to evaluate immune reactions in the lung, and I’m proud that we are able to provide a new answer to that today,” said Dr Abigail Martin, co-founder and CEO of ImmuONE. “It is a testament to our ongoing mission to find better ways to determine chemical safety or toxicity in human lungs.” 

The ImmuPHAGE TM model is composed of alveolar-like macrophage cells assembled in vitro on tissue well plates. These cells closely represent the form and function of human cells. Companies and researchers can then add their target substance to the well plates to evaluate how the cells react.  

This can provide researchers with detailed information about how chemical and biochemical products may irritate the lungs. This is an important advantage over other methods, which only give an “alive” or “dead” result.  

For example, ImmuPHAGE™ has applications in evaluating inhalation toxicology, cytotoxicity screening, and monitoring macrophage uptake. This is useful for clients in a range of sectors, including cosmetics, tobacco, fragrances, agri-chemicals, pharmaceuticals, and academic researchers who want to know more about human lung responses. 

In some cases, ImmuPHAGETM can dramatically reduce or even eliminate the need for animal testing, helping laboratories to achieve their responsible research goals. 

ImmuPHAGETM is fully validated and characterised for cell structure & viability, phagocytic activity and cytokine response. 

About ImmuONE 

ImmuONE is a life science company established in 2019 as a spin-out from the University of Hertfordshire. We specialise in human in vitro cell culture solutions for safety assessment. We are drivers in designing technology to better resemble the alveolar region and the lung’s immune system for reproducible, cell-response readouts for your inhaled mixtures. We also specialise in human in vitro cell culture solutions for safety assessment, designing new platforms to better resemble the alveolar region and immune system of the lungs.  

Add a Comment

Your email address will not be published. Required fields are marked *